Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Stereotactic Aspiration Combined With Tenecteplase for Acute Pontine Hemorrhage

10. november 2026 opdateret af: Dr. Yong Cao, Beijing Tiantan Hospital

A Multicenter, Randomized, Open-Label, Blinded-Endpoint Clinical Trial of Neuronavigation-Guided Stereotactic Aspiration Combined With Tenecteplase for Acute Brainstem Hemorrhage

This multicenter, randomized, open-label, blinded-endpoint clinical study aims to evaluate the safety, feasibility, and potential clinical benefits of neuronavigation-guided stereotactic hematoma aspiration combined with tenecteplase in patients with acute primary brainstem hemorrhage.A total of 140 patients will be randomly assigned in a 1:1 ratio to receive either stereotactic hematoma aspiration combined with tenecteplase and standard medical treatment or standard medical treatment alone.The primary outcome is the proportion of patients with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days. Safety outcomes include mortality, symptomatic rebleeding, and intracranial infection.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

140

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100070
        • Rekruttering
        • Beijing Tiantan Hospital, Capital Medical University
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 79 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥18 years and <80 years.
  • Diagnostic CT completed within 24 hours after symptom onset. Patients with unknown onset time will be excluded. For patients with symptoms first noted during sleep, the time last known well will be considered the onset time.
  • Acute primary brainstem hemorrhage confirmed by head CT, with the predominant hematoma location in the pons (>50% of the hematoma located in the pons); hematoma volume 5-10 mL as measured by the ABC/2 method. The hematoma must be located within the brainstem parenchyma rather than primarily within the ventricles, although extension into the third or fourth ventricle is permitted. For unilateral hemorrhage, a hematoma volume of 3-5 mL is permitted.
  • A repeat CT scan performed 6 hours after symptom onset confirms that the hematoma volume remains within the eligibility range.
  • Glasgow Coma Scale (GCS) score ≥5 and <12 at enrollment.
  • Randomization initiated between 6 and 12 hours after the diagnostic CT.
  • Systolic blood pressure (SBP) <180 mmHg maintained during the 6 hours immediately before randomization.
  • Pre-stroke modified Rankin Scale (mRS) score of 0-1.
  • Voluntary participation in the study with written informed consent provided by the participant or legally authorized representative, as applicable.

Exclusion Criteria:

  • Supratentorial hemorrhage, posterior fossa hemorrhage, or cerebellar hemorrhage.
  • Signs of extremely severe disease, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, or loss of spontaneous respiration.
  • The predominant portion of the hematoma involves the midbrain or medulla.
  • Brainstem hemorrhage secondary to another cerebrovascular or neurological disorder, including cerebral vascular malformation, intracranial aneurysm, other cerebrovascular abnormalities, moyamoya disease, hemorrhagic transformation of ischemic stroke, or hemorrhage related to a neurological tumor.
  • Unstable infratentorial space-occupying lesion, transtentorial herniation, or foramen magnum herniation.
  • Previous history of brainstem hemorrhage.
  • Irreversible brainstem dysfunction, defined as a GCS score ≤4 or ≥12.
  • An indication for craniotomy because of either: (a) progressive deterioration of consciousness; or (b) preoperative cerebral herniation, including signs associated with foramen magnum herniation or uncal herniation.
  • CT evidence indicating a high risk of rebleeding, including a spot sign.
  • Platelet count <100,000/mL or international normalized ratio (INR) >1.4.
  • Any irreversible coagulation disorder, including hemophilia or von Willebrand disease, use of anticoagulants such as warfarin, or a known disorder of clot formation, including a hypercoagulable state.
  • Inability to maintain INR ≤1.4 despite treatment with short- or long-acting hemostatic agents, including recombinant factor VIIa, fresh frozen plasma, or vitamin K.
  • Requirement for long-term anticoagulation. Patients who can undergo temporary reversal of anticoagulation but cannot discontinue warfarin or other anticoagulants for the subsequent 30 days will be excluded.
  • Use within 1 week before symptom onset of dabigatran, apixaban, rivaroxaban, tirofiban, ticagrelor, cilostazol, or clopidogrel.
  • Internal bleeding involving the retroperitoneal, gastrointestinal, or genitourinary systems, or respiratory tract bleeding.
  • Superficial bleeding at a vascular access site (e.g., venous cutdown or arterial puncture) or surgical site.
  • Positive urine or serum pregnancy test in a premenopausal woman without documented surgical sterilization.
  • Known hypersensitivity to tenecteplase.
  • Previous participation in this study with completed randomization.
  • Concurrent participation in another interventional medical study or clinical trial. Participation in an observational study, natural history study, or epidemiological study without an interventional component is permitted.
  • Before randomization, the participant is not expected to survive through the Day 365 follow-up, or has requested do-not-resuscitate (DNR) or do-not-intubate (DNI) status.
  • Any serious concomitant disease expected to substantially affect prognosis, including severe hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune, or hematologic disease.
  • Presence of a mechanical prosthetic heart valve. A bioprosthetic heart valve is permitted.
  • Known embolic risk, including a history of left-sided intracardiac thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is permitted.
  • Any condition requiring immediate emergency treatment outside the study protocol, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, loss of spontaneous respiration, signs of cerebral herniation, progressive respiratory or circulatory failure, or a multidisciplinary determination that immediate craniotomy for hematoma evacuation, decompressive craniectomy, emergency external ventricular drainage, or other emergency treatment is required. Study screening and randomization must not delay necessary emergency treatment.
  • The participant requests conservative treatment or conventional open microsurgical treatment.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Stereotactic Aspiration Combined With Tenecteplase

Participants will receive neuronavigation-guided stereotactic hematoma aspiration followed by intralesional tenecteplase administration, in addition to standard medical treatment.

Neuronavigation-guided stereotactic hematoma aspiration and catheter drainage will be performed within 6 hours after randomization.

Tenecteplase (0.155 mg per dose) will be administered into the hematoma cavity through the drainage catheter after postoperative CT confirms hematoma stability, for up to three doses.

Andre navne:
  • rhTNK-tPA

Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation.

Aktiv komparator: Standard Medical Treatment

Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Participants With GCS Score >8
Tidsramme: 90 days after randomization

Proportion of participants with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days.

90 days after randomization
All-Cause Mortality
Tidsramme: Within 30 days after randomization.

Proportion of participants who die from any cause within 30 days after randomization.

Within 30 days after randomization.

Sekundære resultatmål

Resultatmål
Tidsramme
7-Day All-Cause Mortality
Tidsramme: Within 7 days
Within 7 days
Symptomatic Rebleeding
Tidsramme: Within 72 hours after tenecteplase administration
Within 72 hours after tenecteplase administration
Intracranial Bacterial Infection
Tidsramme: Within 30 days
Within 30 days
Serious Adverse Events (SAEs)
Tidsramme: Within 30 days
Within 30 days
Adverse Events (AEs)
Tidsramme: Within 30 days
Within 30 days
Serious Adverse Events (SAEs)
Tidsramme: Within 365 days
Within 365 days
Adverse Events (AEs)
Tidsramme: Within 365 days
Within 365 days
Proportion With GCS Increase ≥3 Points
Tidsramme: 30 days
30 days
Proportion With Recovery of Consciousness
Tidsramme: 30 days
30 days
Proportion With mRS 0-3
Tidsramme: 90 days
90 days
Proportion With mRS 0-3
Tidsramme: 365 days
365 days
Change in GCS Score Over Time
Tidsramme: From baseline through 90 days after randomization
From baseline through 90 days after randomization

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. april 2026

Primær færdiggørelse (Anslået)

31. december 2028

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

10. november 2026

Først indsendt, der opfyldte QC-kriterier

10. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner